Please login to the form below

Not currently logged in
Email:
Password:

Nabriva Therapeutics appoints chief medical officer

Jennifer Schranz will lead the company’s clinical development business

Jennifer SchranzNabriva Therapeutics, a biopharma focused on treating bacterial infections, has appointed a new chief medical officer in the form of Jennifer Schranz.

Dr Schranz joins Nabriva from Irish biopharma Shire, with nearly two decades of experience in clinical development and medical affairs.

Commenting on the appointment, Dr Colin Broom, chief executive officer of Nabriva, said: “Jennifer has broad expertise in infectious diseases and internal medicine with extensive experience in both clinical development and medical affairs for small molecules and biologics.

“She brings a track record of successful navigating the regulatory submission and approval process, as well as leading medical affairs activities and will be an invaluable member of our team as we continue to advance the legamulin programme toward a potential approval for the treatment of community-acquired bacterial pneumonia.”

Dr Schran’z new role will see her lead clinical development and medical affairs, contributing to the company’s business development strategy.

Her career has seen her hold positions at Shire, ViroPharma, Pfizer, GlaxoSmithKline and Merck & Co.

3rd April 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics